PT  - JOURNAL ARTICLE
AU  - HIROSHI NAKAMURA
AU  - SHIGEHIRO TAMAKI
AU  - TAKAHIRO YAGYUU
AU  - NOBUHIRO YAMAKAWA
AU  - KATSUHIKO HATAKE
AU  - TADAAKI KIRITA
TI  - Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity
AID  - 10.21873/anticanres.13238
DP  - 2019 Mar 01
TA  - Anticancer Research
PG  - 1275--1282
VI  - 39
IP  - 3
4099  - http://ar.iiarjournals.org/content/39/3/1275.short
4100  - http://ar.iiarjournals.org/content/39/3/1275.full
SO  - Anticancer Res2019 Mar 01; 39
AB  - Background/Aim: Cetuximab treatment targets the epidermal growth factor receptor (EGFR) overexpressed in oral cancer. This study aimed to investigate the anti-tumour activity of cetuximab against oral cancer cell lines with respect to antibody-dependent cell-mediated cytotoxicity (ADCC), and determine the correlation between ADCC and EGFR expression. Materials and Methods: EGFR expression in oral cancer cells was measured by quantitative flow cytometric analysis and immunohistochemistry. ADCC activity was measured by 4-h calcein release assays. Results: Cetuximab-mediated ADCC against oral cancer cells was detectable at a concentration of 0.1 μg/ml. A high correlation was observed between the number of EGFR molecules on the surface of oral cancer cells and ADCC (correlation coefficient: 0.847; p=0.032). Conclusion: ADCC is an important mechanism underlying the therapeutic effect of cetuximab, and EGFR expression in tumour cells might serve as a predictive marker to evaluate the effect of cetuximab treatment.